Opendata, web and dolomites

VETEX SIGNED

Deep Vein Thrombosis; A Paradigm Change in Treatment through Drug-Free Clot Removal

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 VETEX project word cloud

Explore the words cloud of the VETEX project. It provides you a very rough idea of what is the project "VETEX" about.

healthcare    dvt    platform    prevent    ulceration    left    completion    strategy    removes    veins    volumes    economics    remove    diagnosed    hours    risks    syndrome    usually    freeflow    amputation    50    last    busting    recurrence    larger    untreated    mortality    witness    swelling    24    post    expedited    segment    therapy    medical    complications    regulatory    upper    thrombosis    clots    600m    limb    coming    clot    steadily    radically    occulsive    embolism    2m    stroke    rates    drugs    heart    extension    deep    risk    opportunity    market    anticoagulation    poor    entry    3rd    helps    attack    commercialise    causing    ireland    securing    involve    72    expensive    skills    form    vein    interventions    stage    icu    team    duty    bleeding    heavier    2021    rate    trend    pulmonary    clinical    hospital    patients    away    trial    approvals    inefficiencies    disease    thrombolytic    thrombotic    extremely    therapies    plan    vetex    treatment    providers    alone    cardiovascular    15    breaking    chronic    device    30    stays   

Project "VETEX" data sheet

The following table provides information about the project.

Coordinator
VETEX MEDICAL LIMITED 

Organization address
address: 218 BUSINESS INNOVATION CENTRE, NUIG
city: GALWAY
postcode: H91 FC85
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Total cost 3˙550˙920 €
 EC max contribution 2˙485˙644 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2021-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VETEX MEDICAL LIMITED IE (GALWAY) coordinator 2˙485˙644.00

Map

 Project objective

Deep Vein Thrombosis is the 3rd leading cardiovascular disease behind heart attack and stroke with 1.2M cases diagnosed each year in the EU and US.

Left untreated, one third of DVT patients will be at risk of clot breaking away causing a Pulmonary Embolism which has a 50% mortality rate. In addition, significant chronic complications often occur such as clot recurrence (30%), chronic limb swelling associated with Post Thrombotic Syndrome (50%), ulceration and amputation.

DVT patients are usually treated with drugs. Anticoagulation therapy alone helps prevent clot extension but it does not remove the clot. Other therapies often involve long hospital stays and often require 24-72 hours in ICU due to the significant bleeding risks associated with heavier duty clot busting (Thrombolytic) drugs. The results are poor for patients with large occulsive clots and who are at risk of bleeding, and extremely expensive for healthcare providers.

Vetex Medical is an early stage medical device based in Ireland that has developed a platform technology that rapidly removes high volumes of clot form the deep veins without the use of thrombolytic drugs, and so will radically challenge the inefficiencies and economics present in the current management of deep vein thrombosis.

Deep Vein Thrombosis in the larger veins of the upper limb represents $600m market opportunity. Interventions in the treatment of DVT have been increasing steadily over the last number of years with growth rates of 15%. This market segment is increasingly ‘on trend’ and set to witness expedited growth over the coming years.

Vetex Medical is ambitious in its’ plan to bring the FreeFlow technology to market in both Europe and the US in 2021, through completion of a Clinical Trial and through securing regulatory approvals to allow market entry. The Vetex Medical Team has the skills and experience to develop and commercialise this novel medical technology and to implement a high growth strategy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VETEX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VETEX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

Totem Spoon (2019)

Interactive Digital Signage with emotional intelligence for smart cities

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More